CN107076749B - 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志 - Google Patents

转移性结直肠癌抗血管发生治疗相关预测和预后生物标志 Download PDF

Info

Publication number
CN107076749B
CN107076749B CN201580049558.1A CN201580049558A CN107076749B CN 107076749 B CN107076749 B CN 107076749B CN 201580049558 A CN201580049558 A CN 201580049558A CN 107076749 B CN107076749 B CN 107076749B
Authority
CN
China
Prior art keywords
vegf
patients
levels
aflibercept
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580049558.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107076749A (zh
Inventor
T·N·西姆斯
B·高
I·洛伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN107076749A publication Critical patent/CN107076749A/zh
Application granted granted Critical
Publication of CN107076749B publication Critical patent/CN107076749B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201580049558.1A 2014-09-16 2015-09-10 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志 Active CN107076749B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US62/051,091 2014-09-16
US201562099630P 2015-01-05 2015-01-05
US62/099,630 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (2)

Publication Number Publication Date
CN107076749A CN107076749A (zh) 2017-08-18
CN107076749B true CN107076749B (zh) 2020-12-29

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580049558.1A Active CN107076749B (zh) 2014-09-16 2015-09-10 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志

Country Status (12)

Country Link
US (2) US10525104B2 (cg-RX-API-DMAC10.html)
EP (1) EP3194974B1 (cg-RX-API-DMAC10.html)
JP (1) JP6692358B2 (cg-RX-API-DMAC10.html)
KR (1) KR102471057B1 (cg-RX-API-DMAC10.html)
CN (1) CN107076749B (cg-RX-API-DMAC10.html)
AU (1) AU2015318207B2 (cg-RX-API-DMAC10.html)
CA (1) CA2960890A1 (cg-RX-API-DMAC10.html)
EA (1) EA036671B1 (cg-RX-API-DMAC10.html)
IL (1) IL250905B (cg-RX-API-DMAC10.html)
MX (1) MX382673B (cg-RX-API-DMAC10.html)
WO (1) WO2016044041A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201701664B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971054A4 (en) 2013-03-14 2017-04-12 Otraces Inc. A method for improving disease diagnosis using measured analytes
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3011988A1 (en) 2016-01-22 2017-07-27 Otraces Inc. Systems and methods for improving disease diagnosis
WO2018181881A1 (ja) * 2017-03-31 2018-10-04 株式会社Ｈｉｒｏｔｓｕバイオサイエンス がん患者の治療効果の予測および／または再発モニタリング
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
US20210012899A1 (en) * 2019-07-13 2021-01-14 Otraces, Inc. Diagnosis for various diseases using tumor microenvironment active proteins
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US12656349B2 (en) 2019-10-17 2026-06-16 Board Of Regents, The University Of Texas System Measurement of bevacizumab-insensitive vascular endothelial growth factor-a
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102711830A (zh) * 2010-01-19 2012-10-03 霍夫曼-拉罗奇有限公司 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志
CN102971001A (zh) * 2009-08-14 2013-03-13 阿勒根公司 使用生长因子再靶向内肽酶治疗癌症的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
CN104634971A (zh) 2010-07-19 2015-05-20 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102971001A (zh) * 2009-08-14 2013-03-13 阿勒根公司 使用生长因子再靶向内肽酶治疗癌症的方法
CN102711830A (zh) * 2010-01-19 2012-10-03 霍夫曼-拉罗奇有限公司 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma;Hidetoshi Hayashi et al.;《Oncotarget》;20140322;第5卷(第9期);第2588-2595页 *
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2;Jennifer L. Spratlin et al.;《JOURNAL OF CLINICAL ONCOLOGY》;20100210;第28卷(第5期);第780-787页 *

Also Published As

Publication number Publication date
IL250905A0 (en) 2017-04-30
JP2017530372A (ja) 2017-10-12
KR102471057B1 (ko) 2022-11-28
MX2017003387A (es) 2018-01-30
US10525104B2 (en) 2020-01-07
EA201790549A1 (ru) 2017-07-31
ZA201701664B (en) 2018-05-30
US20200129589A1 (en) 2020-04-30
MX382673B (es) 2025-03-13
KR20170055972A (ko) 2017-05-22
CN107076749A (zh) 2017-08-18
US20170281725A1 (en) 2017-10-05
JP6692358B2 (ja) 2020-05-13
EP3194974A1 (en) 2017-07-26
WO2016044041A1 (en) 2016-03-24
US11439683B2 (en) 2022-09-13
AU2015318207B2 (en) 2021-11-04
IL250905B (en) 2019-12-31
EA036671B1 (ru) 2020-12-07
CA2960890A1 (en) 2016-03-24
AU2015318207A1 (en) 2017-04-06
EP3194974B1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
US11439683B2 (en) Anti-angiogenic therapy of metastatic colorectal cancer
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
JP6685276B2 (ja) 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
MX2011013578A (es) Biomarcadores y metodos para determinar la eficacia de anticuerpos anti-receptor del factor de crecimiento epidermal (anti-egfr) en terapia de cancer.
KR20120123248A (ko) 악성 종양의 진단 방법
Kraljević et al. Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
CN108496084A (zh) 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法
US20180136216A1 (en) Biomarkers for a Combination Therapy Comprising Lenvatinib and Everolimus
WO2020071457A1 (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant